以DNA拓扑异构酶Ⅱ为靶点的抗癌药物

被引:4
作者
蒙凌华
张永炜
丁健
机构
[1] 中国科学院上海药物研究所肿瘤药理实验室
[2] 中国科学院上海药物研究所肿瘤药理实验室 上海
[3] 上海
关键词
抗癌药物; 拓扑异构酶Ⅱ; 肿瘤;
D O I
暂无
中图分类号
R979.1 [抗肿瘤、抗癌药物];
学科分类号
1007 ;
摘要
DNA拓扑异构酶Ⅱ (TopoisomeraseⅡ ,TOPOⅡ )是一种真核生物生存所必需的泛酶 ,在几乎所有DNA代谢过程中发挥重要作用。TOPOⅡ使一条完整的DNA双链穿过一个移过性的双链断口 ,从而导致DNA解结或解旋。因为TOPOⅡ具有重要的生理功能 ,它已成为抗癌药物的重要作用靶点。以TOPOⅡ为靶点的药物按作用方式可分为 2类 :一类通过稳定TOPOⅡ介导的可切割复合物而杀死肿瘤细胞 ,称为TOPOⅡ毒剂 (TOPOⅡpoison) ;另一类通过抑制TOPOⅡ的催化活性而达到抑制肿瘤的作用 ,称为TOPOⅡ催化抑制剂 (TOPOⅡinhibi tor)。近年来 ,对TOPOⅡ催化机制和药物作用方式的研究取得了很大进展 ,这些发现有助于进一步了解TOPOⅡ的生理功能 ,进而研究出更有效的治疗方案和新的抗癌药。本文介绍了以TOPOⅡ为靶点的抗癌药物的作用机制及其发展现状。
引用
收藏
页码:675 / 683
页数:9
相关论文
共 8 条
[1]  
Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines[J] . A. Pierré,S. Léonce,V. Pérez,G. Atassi.Cancer Chemotherapy and Pharmacology . 1998 (6)
[2]  
In vitro cytotoxicity of S16020-2, a new olivacine derivative[J] . Stéphane Léonce,Valérie Perez,Marie-Rose Casabianca-Pignede,Monique Anstett,Emile Bisagni,Alain Pierré,Ghanem Atassi.INVESTIGATIONAL NEW DRUGS . 1996 (2)
[3]  
Using yeast to study resistance to topoisomerase II-targeting drugs[J] . John L. Nitiss.Cancer Chemotherapy and Pharmacology . 1994 (1)
[4]  
Topoisomerase poisoning activity of novel disaccharide anthracyclines. Guano F, Pourquier P, Tinelli S, et al. Molecular Pharmacology . 1999
[5]  
Induction of apoptosis in human leukemia K562 and gastric carcinoma SGC-7901 cells by salvicine, a novel anticancer compound. Qing C, Jiang C, Ding J. Anti Cancer Drugs . 2001
[6]  
Synthesis and antitumor activity of novel diterpene quinone salvicine and the analogs. Zhang J, Ding J, Tang Q, et al. Bioorg Medi Chem Lett . 1999
[7]  
Cellular resistance to the antitumor DNA topoisomerase Ⅱinhibitor S16020-2: impor-—286—tance of the N-[2 (Dimethylamino) ethyl] carbamoyl side chain. Le MS, Chaminade F, Delaporte C, et al. Molecular Pharmacology . 2000
[8]  
Molecular interactions of DNA-topoisomerase I and Ⅱ inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Nabiev I, Chourpa I, Riou JF, et al. Biochemistry . 1994